International Journal of Drug Delivery Technology
Volume 15, Issue 1

Impact of Docetaxel and Dutasteride-Loaded Nanostructured Lipid Carriers on Male Rats: A Preclinical Evaluation

Patil A A1*, Salve P S2, Sawale J A1 

1Krishna Vishwa Vidyapeeth,, Krishna Institute of Pharmacy, Karad, Satara. Maharashtra, India Pin 415539.

2Krishna Vishwa Vidyapeeth, Department of Pharmacology, Krishna Institute of Medical Sciences, Karad, Satara, Maharashtra, India Pin 415539.

Received: 17th Nov, 2024; Revised: 5th Jan, 2025; Accepted: 13thFeb, 2025; Available Online: 25thMar, 2025

ABSTRACT

In this current investigation, we explored the impacts of Nanostructured Lipid Carriers (NLC) containing docetaxel (Dxt) and dutasteride (Dst) on male rats. Nanostructured lipid carriers (NLC) offer a promising drug delivery platform engineered to augment the efficacy of medications such as docetaxel (Dxt) and docetaxel (Dst) through a tailored production method. However, the potential acute toxicity administered Dxt-Dst NLC remains uncertain. Dxt-Dst-NLC was prepared by melt-emulsification and ultra-sonication techniques Male rats were administered DTX-DST NLC intravenously for 14 days. Throughout the treatment period, diligent observations were made regarding the rats' body weight and food consumption once the treatment concluded. On the 15th day, the rats were euthanized, and their hematological, biochemical, and histopathological profiles were evaluated. Dxt-Dst-NLC administered at 25 mg/kg caused liver damage observed in histopathological observations. Also, the elevation of SGOT and SGPT was observed. We observed inflammation at the injection site on the tail of these findings providing valuable insights that can serve as a foundation for further developing Dxt-Dst NLC as a potential therapeutic medication

Key Words: Docetaxel, Dutasteride, Dxt-Dst-NLC, Wistar rats, Nanostructured Lipid Carriers

How to cite this article: Patil A A, Salve P S, Sawale J A. Impact of Docetaxel and Dutasteride-Loaded Nanostructured Lipid Carriers on Male Rats: A Preclinical Evaluation. International Journal of Drug Delivery Technology. 2025;15(1):238-43. doi: 10.25258/ijddt.15.1.33

REFERENCES References

  1. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. International Journal of Pharmaceutics. 2002; 242:121-128. DOI: 10.1016/s0378-5173(02)00180-1
  2. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as an ocular delivery system for tobramycin. International Journal of Pharmaceutics. 2002; 238:241-245. DOI: 10.1016/s0378-5173(02)00080-7
  3. Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S. Solid lipid nanoparticle suspensions can be produced using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Advanced Drug Delivery Reviews. 2007; 59:444-453. DOI: 10.1016/j.addr.2007.04.010
  4. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. Journal of Controlled Release. 2005; 107:215-228. DOI: 10.1016/j.jconrel.2005.06.006 PMID: 16014318
  5. Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD, Schäfer-Korting M. R Sivaramakrishnan glucocorticoid entrapment into lipid carriers – characterization by paraelectric spectroscopy and influence on dermal uptake. Journal of Controlled Release. 2004; 97:493-502. DOI: 10.1016/j.jconrel.2004.04.001
  6. Zhuang CY, Li N, Wang M et al. Preparation and characterization of vinpocetine-loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. International Journal of Pharmaceutics. 2010; 394:179-185. DOI: 10.1016/j.ijpharm.2010.05.005
  7. zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery– drug release and release mechanism. European Journal of Pharmaceutics and Biopharmaceutics. 1998; 45:149-155. DOI: 10.1016/s0939-6411(97)00150-1
  8. Imran M, Saleem S, Chaudhuri A, Ali J, Baboota S. Docetaxel: an update on its molecular mechanisms, therapeutic trajectory, and nanotechnology in treating breast, lung, and prostate cancer. Journal of Drug Delivery Science and Technology. 2020; 60:10195. DOI: 10.2026/J.Jddst.2020.101959
  9. Ojima I, Lichtenthal B, Lee S, Wang C, Wang X. Taxane anticancer agents: a patent perspective. Expert Opinion on Therapeutic Patents. 2016; 26:1-20. DOI: 10.1517/13543776.2016.1111872
  10. Ghassami E, Varshosaz J, Jahanian-Najafabadi A, Minaiyan M, Rajabi P, Hayati E. Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex (R)nanoparticles for docetaxel delivery in ovarian cancer. International Journal of Nanomedicine. 2018; 13:493-504. DOI: 10.2147/IJN.S152474
  11. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treatment Reviews. 2012; 38:890-903. DOI: 10.1016/j.ctrv.2012.02.011
  12. Wang S, Qiu J, Shi Z, Wang Y, Chen M. Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer. Biotechnology Advances. 2015; 33:224-241. DOI: 10.1016/j.biotechadv.2014.10.011
  13. Qu MH, Zeng RF, Fang S, Dai QS, Li HP, Long JT. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. International Journal of Pharmaceutics. 2014; 474:112-122. DOI: 10.1016/j.ijpharm.2014.08.019
  14. Liang Y, Liu ZY, Wang PY, Li YJ, Wang RR, Xie SY. Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant. Journal of Controlled Release. 2021; 336:396-409. DOI: 10.1016/j.jconrel.2021.06.034
  15. Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives. Journal of Controlled Release. 2016; 240:489-503. DOI: 10.1016/j.jconrel.2016.06.012
  16. Dai W, Wang X, Song G, et al. Combination antitumor therapy with targeted dual-nanomedicines. Advanced Drug Delivery Reviews. 2017; 115:23-45. DOI: 10.1016/j.addr.2017.03.001
  17. Yau YHC, Potenza MN. Stress and eating behaviors. Minerva Endocrinologica. 2013; 38:255-267
  18. Bailey SA, Zidell RH, Perry RW. Relationships between organ weight and body/brain weight in the rat: what is the best analytical endpoint? Toxicologic Pathology. 2004; 32:448-466. DOI: 10.1080/01926230490465874
  19. Ong YS, Saiful Yazan L, Ng WK, Noordin MM, Sapuan S, Foo JB, Tor YS. Acute and subacute toxicity profiles of thymoquinone- loaded nanostructured lipid carrier in BALB/c mice. International Journal of Nanomedicine. 2016; 11:5905-5915. DOI: 10.2147/IJN.S114205
  20. Weingand K, Bloom J, Carakostas M, et al. Clinical pathology testing recommendations for nonclinical toxicity and safety studies. AACC-DACC/ASVCP Joint Task Force. Toxicology. Toxicologic Pathology. 1992; 20:539-543. DOI: 10.1177/0192623392020003217
  21. Osuala FI, Otitoloju AA, Igwo-Ezikpe MN. The usefulness of liver and kidney function parameters as biomarkers of ‘heavy metals’ exposure in a mammalian model Mus musculus. African Journal of Biochemistry Research. 2014; 8:65-73. DOI: 10.5897/AJBR2013.0728
  22. Wang Y, Juan LV, Ma X et al. Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: altered iron metabolism and its implication as an acute hemosiderin formation model. Current Drug Metabolism. 2010; 11:507-515. DOI: 10.2174/138920010791636149
  23. Mezei M, Sager RW, Stewart WD, DeRuyter AL. Dermatitis effect of nonionic surfactants. I. Gross, microscopic, and metabolic changes in rabbit skin treated with nonionic surface-active agents. Journal of Pharmaceutical Sciences. 1966; 55:584-590. DOI: 10.1002/jps.2600550611